Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing Baltimore, MD

Champions Oncology (formerly

Champions Biotechnology) Completes $9.4 Million Financing

Baltimore, MD April 5,

2011 - Champions Oncology, Inc. (OTC: CSBR) ("the Company",

formerly known as Champions Biotechnology, Inc.) announced today it has

completed the private placement of 12.5 million shares of its common stock

at a price of $0.75 per share, resulting in gross proceeds to the company of

Proceeds from the financing will be

Up to $1.4 million of the

proceeds will be used to repurchase shares from certain shareholders in one or

more privately negotiated transactions at a discount to $0.75 per share. The

Company has utilized $960,000 of this $1.4 million allocation of the

proceeds to complete the repurchase of two million shares from a majority

shareholder at a price of $0.48 per share.

Concurrent with the closing of the

investment, the Company will issue 1,010,000 warrants to certain investors

which will entitle the holders to purchase additional common shares at $0.90

per share for a period of five years, following the date of issuance. In

addition, purchasers of the shares will have the right to require the Company

to repurchase the purchased shares (the "Put Option") for cash for

$0.75 upon a change of control or sale of substantially all of the

company's assets. The Put Option will terminate upon the achievement of

The offer and sale of the shares

have not been registered under the Securities Act of 1933, as amended, and the

shares may not be offered or sold in the United States absent registration

under such act and applicable state securities laws or an applicable exemption

from those registration requirements. The Company has agreed to file a

registration statement covering the resale of the common stock issued in the

private placement. This press release shall not constitute an offer to sell or

the solicitation of an offer to buy nor shall there be any sale of these

securities in any jurisdiction in which such offer, solicitation or sale would

be unlawful prior to the registration or qualification under the securities

laws of any such jurisdiction.

This press release contains

"forward-looking statements" (within the meaning of the Private

Securities Litigation Act of 1995) that inherently involve risk and

uncertainties. Champions Oncology generally uses words such as

"believe," "may," "could,"

"will," "intend," "expect,"

"anticipate," "plan," and similar expressions to

identify forward-looking statements. One should not place undue reliance on

these forward-looking statements. The Company's actual results could

differ materially from those anticipated in the forward-looking statements for

many unforeseen factors. See the Company's Form 10-K for

the fiscal year ended April 30, 2010 for a discussion of such risks,

uncertainties and other factors. Although the Company believes the expectations

reflected in the forward-looking statements are reasonable, they relate only to

events as of the date on which the statements are made, and Champions

Oncology's future results, levels of activity, performance or

achievements may not meet these expectations. The Company does not intend to

update any of the forward-looking statements after the date of this press

release to conform these statements to actual results or to changes in the

Company's expectations, except as required by law.

CHAMPIONS Oncology, Inc.

855 N. Wolfe Street, Suite 619

Baltimore, Maryland 21205 USA.